EP3419661A4 - METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE - Google Patents

METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE Download PDF

Info

Publication number
EP3419661A4
EP3419661A4 EP17757336.7A EP17757336A EP3419661A4 EP 3419661 A4 EP3419661 A4 EP 3419661A4 EP 17757336 A EP17757336 A EP 17757336A EP 3419661 A4 EP3419661 A4 EP 3419661A4
Authority
EP
European Patent Office
Prior art keywords
vaccine
composition
treating cancer
skin lesion
lesion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP17757336.7A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3419661A1 (en
Inventor
Tim Ioannides
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hpvvax LLC
Original Assignee
Hpvvax LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hpvvax LLC filed Critical Hpvvax LLC
Publication of EP3419661A1 publication Critical patent/EP3419661A1/en
Publication of EP3419661A4 publication Critical patent/EP3419661A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Anesthesiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
EP17757336.7A 2016-02-27 2017-02-24 METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE Pending EP3419661A4 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662300785P 2016-02-27 2016-02-27
US201662328487P 2016-04-27 2016-04-27
US201662338183P 2016-05-18 2016-05-18
US201762444576P 2017-01-10 2017-01-10
US201762455434P 2017-02-06 2017-02-06
PCT/US2017/019433 WO2017147475A1 (en) 2016-02-27 2017-02-24 Method and composition for treating cancer or skin lesion using a vaccine

Publications (2)

Publication Number Publication Date
EP3419661A1 EP3419661A1 (en) 2019-01-02
EP3419661A4 true EP3419661A4 (en) 2019-10-23

Family

ID=59686556

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17757336.7A Pending EP3419661A4 (en) 2016-02-27 2017-02-24 METHOD AND COMPOSITION FOR TREATING CANCER OR SKIN INJURY USING A VACCINE

Country Status (16)

Country Link
EP (1) EP3419661A4 (ko)
JP (3) JP2019506435A (ko)
KR (1) KR20180112043A (ko)
CN (1) CN108883168A (ko)
AU (1) AU2017223970B2 (ko)
BR (1) BR112018067550A2 (ko)
CA (1) CA3015519A1 (ko)
CL (1) CL2018002438A1 (ko)
CO (1) CO2018009205A2 (ko)
HK (1) HK1256935A1 (ko)
IL (1) IL261340B2 (ko)
MX (1) MX2018010338A (ko)
MY (1) MY194694A (ko)
SG (1) SG11201807080UA (ko)
WO (1) WO2017147475A1 (ko)
ZA (1) ZA201805679B (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114127095B (zh) * 2019-07-19 2024-04-09 神州细胞工程有限公司 嵌合的人乳头瘤病毒11型l1蛋白
WO2024097051A1 (en) * 2022-10-31 2024-05-10 Pyrojas Inc. Immunotherapy compositions and methods of use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087614A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
SG177269A1 (en) * 2009-06-25 2012-02-28 Glaxosmithkline Biolog Sa Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
EP2717884A1 (en) * 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
JP2015514696A (ja) * 2012-03-18 2015-05-21 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ヒト・パピローマウイルスに対するワクチン接種方法
US20130251782A1 (en) * 2012-03-22 2013-09-26 Leo Laboratories Limited Topical application of ingenol mebutate with occlusion
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2016538333A (ja) * 2013-10-13 2016-12-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー ヒトパピローマウイルス治療ワクチン
US10286058B2 (en) * 2014-01-13 2019-05-14 Baylor Research Institute Vaccines against HPV and HPV-related diseases
US10238729B2 (en) * 2014-10-24 2019-03-26 Hpvvax, Llc Cancer and skin lesion treatment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087614A2 (en) * 2001-04-27 2002-11-07 Glaxosmithkline Biologicals S.A. Multivalent vaccine comprising an hiv antigen and an hsv antigen and/or an hpv antigen
WO2003078455A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus like particle from papillomavirus and their use in vaccine
WO2003077942A2 (en) * 2002-03-18 2003-09-25 Glaxosmithkline Biologicals Sa Virus-like particles of human papillomavirus
WO2010120266A1 (en) * 2009-04-13 2010-10-21 Inserm, Institut National De La Sante Et De La Recherche Medicale Hpv particles and uses thereof
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. SCHILLING ET AL: "Coadministration of a 9-Valent Human Papillomavirus Vaccine With Meningococcal and Tdap Vaccines", PEDIATRICS, vol. 136, no. 3, 1 September 2015 (2015-09-01), pages e563 - e572, XP055519294, ISSN: 0031-4005, DOI: 10.1542/peds.2014-4199 *
ANNA J. NICHOLS ET AL: "Combined Systemic and Intratumoral Administration of Human Papillomavirus Vaccine to Treat Multiple Cutaneous Basaloid Squamous Cell Carcinomas", JAMA DERMATOLOGY, vol. 154, no. 8, 1 August 2018 (2018-08-01), US, pages 927, XP055537673, ISSN: 2168-6068, DOI: 10.1001/jamadermatol.2018.1748 *
ANNA TADDIO ET AL: "A randomized controlled trial of analgesia during vaccination in adults", VACCINE, vol. 28, no. 32, 1 July 2010 (2010-07-01), AMSTERDAM, NL, pages 5365 - 5369, XP055620773, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2010.05.015 *
GARLAND SUZANNE M ET AL: "Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine", VACCINE, vol. 33, no. 48, 3 August 2015 (2015-08-03), pages 6855 - 6864, XP029332047, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2015.08.059 *

Also Published As

Publication number Publication date
KR20180112043A (ko) 2018-10-11
MX2018010338A (es) 2018-11-09
SG11201807080UA (en) 2018-09-27
MY194694A (en) 2022-12-15
AU2017223970B2 (en) 2022-01-27
JP2021155448A (ja) 2021-10-07
AU2017223970A1 (en) 2018-09-13
JP2019506435A (ja) 2019-03-07
CL2018002438A1 (es) 2019-01-04
WO2017147475A1 (en) 2017-08-31
HK1256935A1 (zh) 2019-10-04
JP2023110038A (ja) 2023-08-08
CN108883168A (zh) 2018-11-23
BR112018067550A2 (pt) 2019-10-01
IL261340A (en) 2018-11-29
CA3015519A1 (en) 2017-08-31
IL261340B1 (en) 2023-03-01
IL261340B2 (en) 2023-07-01
ZA201805679B (en) 2019-11-27
CO2018009205A2 (es) 2018-09-20
EP3419661A1 (en) 2019-01-02

Similar Documents

Publication Publication Date Title
EP3367986A4 (en) TISSUE TREATMENT DEVICE AND METHOD
EP3551100A4 (en) MEDICAL DEVICES FOR TREATING HARD TISSUES AND RELATED PROCESSES
EP3634442A4 (en) METHODS OF TREATMENT AND PREVENTION OF DISEASES
EP3160566A4 (en) Tissue sampling and cancer treatment methods and apparatus
EP3518783A4 (en) TISSUE REDUCTION APPARATUS AND METHODS
EP3277166A4 (en) Method and apparatus for treating soft tissue injury
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
EP3347025A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP3445265A4 (en) SKIN TREATMENT DEVICE AND METHOD
EP3391901A4 (en) METHOD FOR PREVENTING OR TREATING HEPATIC TISSUE LESIONS AND RELATED DISEASES
EP3589659A4 (en) CANCER TREATMENT COMPOUNDS AND METHODS
EP3568195A4 (en) MUSCULOSKELETAL TISSUE TREATMENT SYSTEMS AND METHODS
EP3407961A4 (en) SKIN TREATMENT DEVICE AND METHOD
EP3554310A4 (en) PACKAGED SKIN TREATMENT COMPOSITION AND METHOD
EP3411122A4 (en) CANCER VACCINES AND TREATMENT METHODS THEREWITH
EP3352729A4 (en) METHODS AND COMPOSITIONS FOR TREATING SKIN
EP3688023A4 (en) PROCEDURES AND COMPOSITIONS FOR CANCER TREATMENT
EP3697767A4 (en) CANCER TREATMENT COMPOUNDS AND METHODS
EP3455761A4 (en) METHOD AND MATERIALS FOR STADIUM DETERMINATION AND TREATMENT OF CANCER
HK1256935A1 (zh) 使用疫苗治療癌症或皮膚病變的方法和組合物
EP3677267A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF TUMORS, METHOD AND USES THEREOF
EP3443090A4 (en) USE OF MIR-223-3P AS CANCER THERAPEUTIC AND METHOD FOR THE TREATMENT OF CANCER THEREWITH
EP3563856A4 (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER AND USE THEREOF
EP3576761A4 (en) HERBO-MINERAL FORMULATION FOR THE TREATMENT OF CANCER AND RELATED PREPARATION PROCESS
EP3236961A4 (en) Pharmaceutical composition for preventing or treating cancer and method using thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180822

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190925

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/12 20060101AFI20190919BHEP

Ipc: A61P 35/00 20060101ALI20190919BHEP

Ipc: C12N 7/00 20060101ALI20190919BHEP

Ipc: C07K 14/005 20060101ALI20190919BHEP

Ipc: A61P 31/20 20060101ALI20190919BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20201028

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS